NEW YORK, Dec. 3, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), announced the expansion of PCT's relationship with ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC), a clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers, for current good manufacturing practices (cGMP) and development services for ImmunoCellular's dendritic cell-based vaccines. PCT currently manufactures ICT-121, a dendritic cell vaccine targeting CD133 cells, in a Phase 1 clinical trial for recurrent glioblastoma multiforme (GBM) pursuant to a Services Agreement between the companies. PCT also manufactured Phase 2 clinical supplies of ICT-107, a dendritic cell-based vaccine targeting six tumor-associated antigens for newly diagnosed GBM. Under this newly executed Services Agreement, PCT will manufacture clinical supplies of ICT-140, a dendritic cell vaccine targeting seven ovarian cancer antigens, using process improvements PCT will develop that can be applied to the manufacture of all ImmunoCellular's current vaccine product candidates, ICT-107, ICT-121 and ICT-140. These process improvements are intended to increase quality, consistency, efficiency, and cost-effectiveness, and support ImmunoCellular's vaccine manufacturing requirements for conducting potential Phase 3 registration trials and for commercial manufacturing should these therapies receive Food and Drug Administration approval.
NeoStem's Subsidiary, Progenitor Cell Therapy LLC ("PCT"), Expands Manufacturing Relationship With ImmunoCellular Therapeutics For Dendritic Cell Vaccines
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts